| A Global Web Site About Investigating Dovitinib (TKI258)

GOLD Trials

The GOLD (Global Oncologic Learnings for Dovitinib) Trials are a series of global initiatives led by Novartis that encompass a broad range of malignancies, breast cancer, gastric cancer, and hepatocellular carcinoma (HCC). Through this program Novartis is conducting clinical studies of dovitinib (TKI258) as a single agent and in combination with other agents.1

Welcome to GOLD Trials, a Global Web Site About Dovitinib (TKI258)

Dovitinib (TKI258) is an investigational cancer treatment in development by Novartis.

This is a global Web site for the GOLD clinical trials and is intended for healthcare professionals around the world. GOLD stands for Global Oncologic Learnings for Dovitinib.